[Prévia] [Próxima] [Prévia por assunto] [Próxima por assunto]
[Índice cronológico]
[Índice de assunto]
Fw: 2009 Bayesian Biostatistics Conference, Houston
- Subject: Fw: 2009 Bayesian Biostatistics Conference, Houston
- From: "Alexandra M. Schmidt" <alex@im.ufrj.br>
- Date: Fri, 12 Dec 2008 16:16:29 -0300
---------- Forwarded Message -----------
From: Valencia Meeting <valenciameeting@uv.es>
To: Valencia List 1:;
Sent: Fri, 12 Dec 2008 18:15:41 +0100
Subject: 2009 Bayesian Biostatistics Conference, Houston
Hi all
Please find below info on the next Bayesian Biostatistics Conference
Best,
Jose
____________
From Telba Irony
Bayesian Biostatistics Conference
January 26 - 28, 2009
Houston, Texas U.S.A.
Program Committee
Donald A. Berry, co-chair (M. D. Anderson)
Telba Z. Irony, co-chair (CDRH, FDA)
Kathryn Chaloner (University of Iowa)
Stacy R. Lindborg (Eli Lilly and Company)
Andrew Mugglin (University of Minnesota)
Sharon-Lise T. Normand (Harvard University)
Registration - Available online through January 20, 2009
A late fee of $50 will be assessed for
registrations received after January 11, 2009.
Online registration and additional information available at
http://www.mdanderson.org/departments/biostats
Registration (U.S. dollars):
$300 - general registration
$150 - special student discount
Registration fees cover:
* all sessions
* handout materials
* continental breakfast days 1-3
* boxed lunch days 1 & 2
* reception & hors d'oeuvres day 1
Partially funded by the Department of Biostatistics
The University of Texas M. D. Anderson Cancer Center
Program
Monday, January 26, 2009
8:00 am Registration check-in and on-site registration
8:00 am - 9:00 am Continental breakfast (provided)
Morning Session
9:00 am - 11:45 am Short Course I: Title TBA
Donald A. Berry (M. D. Anderson)
15-minute break at 10:15 am
11:45 am - 1:00 PM - Boxed lunch (provided)
Afternoon Sessions
1:00 PM - 3:30 PM Short Course II: Title TBA
Gary L. Rosner (M. D. Anderson)
15-minute breaks at 2:15 and at 3:30 PM
3:45 PM - 5:30 PM Keynote Speaker: Donald B. Rubin (Harvard University)
6:30 PM - 9:00 PM Welcome Reception
6:30 - 7:30 - Hors d'oeuvres and cash bar
7:30 - 9:00 - Panel Discussion : Topic TBA
PANELISTS:
Telba Z. Irony (CDRH, FDA), Moderator
Jim Berger (Duke University)
Donald A. Berry (M. D. Anderson)
Gregory Campbell (CDRH, FDA)
A. Lawrence Gould (Merck)
Tuesday, January 27, 2009
8:00 AM - 9:00 AM Continental breakfast (provided)
Registration available
Morning Sessions
9:00 AM - 10:30 AM Session 1: Statistical
Genetics Applied to Biomedical Sciences
Speaker: Paola Sebastiani (Boston University)
Title: Bayesian Modeling of Complex Traits: Diagnostic Versus Prognostic
Models
Speaker: Marta Blangiardo (Imperial College Centre for Biostatistics, UK)
Collaborator: Sylvia Richardson (Imperial College Centre for Biostatistics,
UK)
Title: A Bayesian Calibration Model for Combining
Different Preprocessing Methods in Affymetrix
Chips
Speaker: TBA
Title: TBA
Chair: Donald A. Berry (M. D. Anderson)
10:30 AM - 10:45 AM Break
10:45 AM - 12:15 PM Session 2: Bayesian Clinical Trials
Speaker: David Ohlssen (Novartis Pharmaceuticals)
Collaborators: Hayley Jones (MRC Biostatistics
Unit, UK), Beat Neuenschwander, Amy Racine, and
Michael Branson (Novartis Pharma, Switzerland)
Title: A Case Study Examining the Use of Bayesian
Methods for Subgroup Analysis in Clinical Trials
Speaker: Peter Müller (M. D. Anderson)
Title: Borrowing Strength with Non-exchangeable Priors Over Subpopulations
10:45 AM - 12:15 PM
Speaker: Alice R. Pressman (Kaiser Foundation
Research Institute) Collaborators: Andrew Avins
(University of California SF) and Alan Hubbard
(UC Berkeley)
Title: A Comparison of Two Worlds: How Does Bayes Hold Up to the Status Quo?
Chair: Kathryn Chaloner (University of Iowa)
12:15 PM - 1:30 PM Boxed lunch (provided)
Afternoon Parallel Sessions 3 & 4
1:30 PM - 3:00 PM Session 3: Bayesian
Clinical Trials: Improving Cancer Research
Speaker: Stuart Bailey (Novartis Pharma) Collaborator: Daniel Lorand
(Novartis)
Title: The Simultaneous Assessment of Safety and
Efficacy: An Application of a Bayesian Model to
Determine the Optimal Biological Dose in Oncology
Phase I Dose Escalation
Speaker: Brani Vidakovic (Georgia Institute of Technology and Emory
University)
Collaborators: André Rogatko (Samuel Oschin Comprehensive Cancer Institute),
Mourad Tighiouart (Emory University), and Pulak Ghosh (Novartis Pharma)
Title: Individualized Patient Dosing in Cancer Clinical Trials
Speaker: Andrew Mugglin (University of Minnesota)
Collaborator: Nathan Enas (Eli Lilly and Company)
Title: An Efficient Randomized Bayesian Phase II
Study Design: A Model and a Case Study
Chair: Sharon-Lise T. Normand (Harvard University)
1:30 PM - 3:00 PM Session 4: Bayesian Methods Influencing Health Policy
Speaker: A. James O'Malley (Harvard University)
Collaborators: Sharon-Lise T. Normand (Harvard
University) and Richard Frank (National Bureau of
Economic Research)
Title: Traditional Instrumental Variables Methods
Versus Likelihood and Bayesian Approaches for
Comparing Antipsychotic Medications
Speaker: Yulei He (Harvard University)
Collaborators: Bob Wolfe and Sharon-Lise T. Normand (Harvard University)
Title: The Healthcare World Is Not Flat:
Understanding Geographical Variations in the
Quality of Hospital Care
Speaker: Gillian D. Sanders (Duke University)
Collaborator: Scott Schmidler (Duke University)
Title: Effect of HPV Vaccine Characteristics and
Implementation Strategies on the Incidence of
Disease
Chair: Stacy R. Lindborg (Eli Lilly and Company)
3:00 PM - 3:15 PM Break
Afternoon Parallel Sessions 5 & 6
3:15 PM - 4:45 PM Session 5: Bayesian Clinical Trials: Dose Selection Methods
Speaker: Yu-Hui Chang (University of Iowa)
Collaborators: Kathryn Chaloner and Patricia Winokur (University of Iowa)
Title: An Adaptive Dose Exploration Design for
the Estimation of Human Colonizing Dose 50 and
Human Colonizing Dose 90
Speaker: François Vandenhende (ClinBAY, Belgium)
Collaborators: Davorka Tomic, Alexander Coppell,
Ping He, Gilmore O'Neill (Biogen Idec, Inc.), and
David J. Brooks (Imperial College, UK)
Title: Bayesian Dose Selection Strategy in
Biomarker Trials: A Case Study Using Brain Imaging
Speaker: Peter F. Thall (M. D. Anderson)
Title: Utility-based Optimization of Combination
Therapy Using Ordinal Toxicity and Efficacy in
Phase I/II Trials
Chair: Andrew Mugglin (University of Minnesota)
3:15 PM - 4:45 PM Session 6: Bayesian Methods in
the Analysis of Clinical Trial Data
Speaker: Joseph W. Hogan (Brown University)
Collaborator: Joo Yeon Lee (FDA)
Title: Construction and Calibration of Priors for
Handling Missing Data in Clinical Trials
Speaker: Zachary Skrivanek, (Eli Lilly and Company)
Collaborators: Brenda L. Gaydos (Eli Lilly and
Company) and Scott M. Berry (Berry Consultants)
Title: Proof by Simulation: A Case Study
Speaker: Michael Daniels, (University of Florida, Gainesville)
Collaborators: C. Wang (University of Florida,
Gainesville) and Daniel O. Scharfstein (Johns
Hopkins University)
Title: Bayesian Semiparametric Selection Models
with Application to a Breast Cancer Prevention
Trial
Chair: Stacy R. Lindborg (Eli Lilly and Company)
5:30 PM - 8:00 PM Poster Session
Wednesday, January 28, 2009
8:00 AM - 9:00 AM Continental Breakfast (provided)
Morning Sessions
9:00 AM - 10:30 AM Session 7: Bayesian Decision Theory
Speaker: David Draper (University of California, Santa Cruz)
Title: Bayesian Decision Theory in Clinical Trial
Design and Analysis: The Utility of Utility
Speaker: J. Andrés Christen (CIMAT, México)
Collaborators: Peter Müller, J. Kyle Wathen, and Judith Wolf (M. D. Anderson)
Title: A Bayesian Randomized Clinical Trial: A
Decision Theoretic Sequential Design
Speaker: Robert Parker (Amgen, Inc.)
Collaborator: Joseph Ibrahim (University of North Carolina)
Title: Assessing Similarity to Existing Drugs to
Decide Whether to Continue Drug Development
Chair: Telba Z. Irony (CDRH, FDA)
10:30 AM - 10:45 AM Break
10:45 AM - 12:15 PM Session 8: Bayesian Adaptive Clinical Trials
Speaker: Jason T. Connor (Berry Consultants)
Collaborators: Donald A. Berry (M. D. Anderson),
Michael Snabes (BioSante Pharmaceuticals, Inc.),
and William White (University of Connecticut
Health Center)
Title: A Phase III Cardiovascular Safety Trial Using A Bayesian Adaptive
Design
Speaker: Frank E. Harrell, Jr. (Vanderbilt University School of Medicine)
Title: Case Study of a Maximally Flexible
Bayesian Design in Biologics Research with a
Skeptical Prior and Cox Model-based Analysis
Speaker: Bradley P. Carlin, (University of Minnesota)
Collaborator: Brian Hobbs (University of Minnesota)
Title: Power Priors for Adaptive Incorporation of
Historical Information in Clinical Trials
Chair: Sharon-Lise T. Normand (Harvard University)
12:15 PM Closing Remarks - Program Committee
--
__________________________________________________________________
The Valencia Mailing List contains about 2,000
entries of people interested in Bayesian
Statistics. It sends information about the
Valencia International Meetings on Bayesian
Statistics, and other material of interest to the
Bayesian community.
If you receive this message, you are on the Valencia List.
1. If you use an anti-spam programme, please let <valenciameeting@uv.es> in.
2. If you want to be deleted, please reply "unsubscribe"
3. If we are not using your preferred e-mail
address, please reply with the correct one.
Valencia Meetings Mailing List (c/o Prof. Dr. Jose M. Bernardo)
Dept. Estadistica, Universidad de Valencia
Tel +34 96 354 4354 Fax +34 96 364 3560 (direct),
Tel +34 96 354 3087, Fax +34 96 354 3238 (office)
<valenciameeting@uv.es>
Valencia / ISBA Ninth World Meeting on Bayesian Statistics
Spain, June 2010
www.uv.es/valenciameeting
___________________________________________________________________
------- End of Forwarded Message -------
-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*
Alexandra Mello Schmidt, PhD
Professora Adjunta
Instituto de Matemática - UFRJ
Caixa Postal 68530 Rio de Janeiro - RJ
CEP:21.945-970 Brasil
Tel: 0055 21 2562 7505 Ramal (Extension) 204
Fax: 0055 21 2562 7374
http://www.dme.ufrj.br/~alex
-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*
Cash your dreams before they slip away. Lose your dreams and you lose your
mind (From the "God of Small things").
Gentileza gera gentileza (Profeta Gentileza)
<!doctype html public "-//W3C//DTD W3 HTML//EN">
<html><head><style type="text/css"><!--
blockquote, dl, ul, ol, li { padding-top: 0 ; padding-bottom: 0 }
--></style><title>2009 Bayesian Biostatistics Conference,
Houston</title></head><body>
<div><font face="Helvetica" color="#000000">Hi all</font><br>
<font face="Helvetica" color="#000000"></font></div>
<div><font face="Helvetica" color="#000000">Please find below
info on the next Bayesian Biostatistics Conference<br>
<br>
Best,<br>
<br>
Jose<br>
<br>
____________<br>
<br>
<b>From Telba Irony<br>
<br>
</b></font><font face="Times New Roman" size="+2"
color="#000000">Bayesian Biostatistics Conference<br>
January 26 - 28, 2009<br>
Houston, Texas U.S.A.<br>
</font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" size="+1"
color="#000000"><b>Program Committee</b></font><font face="Times"
size="+1" color="#000000"><br>
</font><font face="Times New Roman" color="#000000">Donald A. Berry,
co-chair (M. D. Anderson)<br>
Telba Z. Irony, co-chair (CDRH, FDA)<br>
Kathryn Chaloner (University of Iowa)<br>
Stacy R. Lindborg (Eli Lilly and Company)<br>
Andrew Mugglin (University of Minnesota)<br>
Sharon-Lise T. Normand (Harvard University)<br>
<br>
<b>Registration - Available online through January 20, 2009<br>
</b>A late fee of $50 will be assessed for registrations received
after January 11, 2009.<br>
</font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000">Online
registration and additional information available at<br>
http://www.mdanderson.org/departments/biostats<br>
</font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000">Registration (U.S.
dollars):<br>
$300 - general registration<br>
$150 - special student discount<br>
Registration fees cover:<br>
* all sessions<br>
* handout materials<br>
* continental breakfast days 1-3<br>
* boxed lunch days 1 & 2<br>
* reception & hors d'oeuvres day 1<br>
<br>
Partially funded by the Department of Biostatistics<br>
The University of Texas M. D. Anderson Cancer Center<br>
</font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" size="+1"
color="#000000"><b>Program<br>
</b></font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000"><u><b>Monday,
January 26, 2009<br>
</b></u></font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000">8:00
am <b> Registration check-in and on-site
registration</b></font><font face="Times" color="#000000"><br>
<br>
</font><font face="Times New Roman" color="#000000">8:00 am - 9:00
am<b> Continental breakfast</b> (provided)<br>
</font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000"><b>Morning
Session</b></font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000">9:00 am - 11:45
am <b> Short Course I: Title TBA<br>
</b>Donald A. Berry (M. D. Anderson)<br>
<br>
15-minute break at 10:15 am<br>
</font><font face="Times" color="#000000"><x-tab>
</x-tab><x-tab>
</x-tab><x-tab>
</x-tab><x-tab> </x-tab><br>
</font><font face="Times New Roman" color="#000000">11:45 am - 1:00 PM
-<b> Boxed lunch</b> (provided)<br>
</font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000"><b>Afternoon
Sessions</b></font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000">1:00 PM - 3:30
PM <b> Short Course II: Title TBA</b></font><font face="Times"
color="#000000"><br>
</font><font face="Times New Roman" color="#000000">Gary L. Rosner (M.
D. Anderson)<br>
</font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000">15-minute breaks
at 2:15 and at 3:30 PM<br>
<br>
3:45 PM - 5:30 PM <b> Keynote Speaker:</b> Donald B. Rubin
(Harvard University)<br>
</font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000">6:30 PM - 9:00
PM<b> Welcome Reception</b><br>
6:30 - 7:30 - Hors d'oeuvres and cash bar<br>
7:30 - 9:00 - Panel Discussion : Topic TBA<br>
<x-tab> </x-tab><x-tab>
</x-tab><x-tab> </x-tab><br>
<b>PANELISTS:<br>
</b>Telba Z. Irony (CDRH, FDA), Moderator<br>
Jim Berger (Duke University)<br>
Donald A. Berry (M. D. Anderson)<br>
Gregory Campbell (CDRH, FDA)<br>
A. Lawrence Gould (Merck)<br>
</font><font face="Times" color="#000000"><br>
<br>
</font><font face="Times New Roman" color="#000000"><u><b>Tuesday,
January 27, 2009<br>
</b></u></font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000">8:00 AM - 9:00
AM<b> Continental breakfast</b> (provided)</font><font face="Times"
color="#000000"><b><br>
</b></font><font face="Times New Roman" color="#000000">Registration
available<br>
</font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000"><b>Morning
Sessions</b></font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000">9:00 AM - 10:30
AM<x-tab> </x-tab><b>Session 1: Statistical
Genetics Applied to Biomedical Sciences</b></font><font face="Times"
color="#000000"><br>
<b><br>
</b></font><font face="Times New Roman" color="#000000"><b>Speaker:
Paola Sebastiani</b> (Boston University)<br>
<b>Title:</b><font size="-3"> Bayesian Modeling of Complex Traits:
Diagnostic Versus Prognostic Models<br>
</font></font><font face="Times"
color="#000000"><x-tab>
</x-tab><x-tab>
</x-tab><x-tab>
</x-tab><x-tab> </x-tab><br>
</font><font face="Times New Roman" color="#000000"><b>Speaker: Marta
Blangiardo</b> (Imperial College Centre for Biostatistics, UK)<br>
Collaborator: Sylvia Richardson (Imperial College Centre for
Biostatistics, UK)<br>
<b>Title:</b> A Bayesian Calibration Model for Combining Different
Preprocessing Methods in Affymetrix Chips<br>
</font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000"><b>Speaker:</b>
TBA<br>
<b>Title:</b> TBA<br>
<br>
<b>Chair:</b> Donald A. Berry (M. D. Anderson)<br>
<br>
10:30 AM - 10:45 AM <b> Break<br>
</b></font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000">10:45 AM - 12:15
PM<x-tab> </x-tab><b>Session 2: Bayesian Clinical Trials<br>
</b></font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000"><b>Speaker: David
Ohlssen</b> (Novartis Pharmaceuticals) <br>
Collaborators: Hayley Jones (MRC Biostatistics Unit, UK), Beat
Neuenschwander, Amy Racine, and Michael Branson (Novartis Pharma,
Switzerland)<br>
<b>Title:</b> A Case Study Examining the Use of Bayesian Methods for
Subgroup Analysis in Clinical Trials<br>
</font><font face="Times" color="#000000"><x-tab>
</x-tab><x-tab>
</x-tab><x-tab>
</x-tab><x-tab> </x-tab><br>
</font><font face="Times New Roman" color="#000000"><b>Speaker: Peter
Müller</b> (M. D. Anderson)<br>
<b>Title:</b> Borrowing Strength with Non-exchangeable Priors Over
Subpopulations<br>
</font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" size="+1"
color="#000000">10:45</font><font face="Times New Roman" size="-3"
color="#000000"> AM</font><font face="Times New Roman" size="+1"
color="#000000"> - 12:15</font><font face="Times New Roman" size="-3"
color="#000000"> PM</font><font face="Times" size="+1"
color="#000000"><x-tab> </x-tab><br>
</font><font face="Times New Roman" color="#000000"><b>Speaker: Alice
R. Pressman</b> (Kaiser Foundation Research Institute) Collaborators:
Andrew Avins (University of California SF) and Alan Hubbard (UC
Berkeley)<br>
<b>Title:</b> A Comparison of Two Worlds: How Does Bayes Hold Up to
the Status Quo?<br>
</font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000"><b>Chair:</b>
Kathryn Chaloner (University of Iowa)<br>
<br>
12:15 PM - 1:30 PM <b> Boxed lunch</b> (provided)<br>
<br>
<b>Afternoon Parallel Sessions 3 & 4<x-tab>
</x-tab><x-tab>
</x-tab><x-tab>
</x-tab><x-tab> </x-tab><br>
</b>1:30 PM - 3:00 PM</font><font face="Times"
color="#000000"><b><x-tab>
</x-tab></b></font><font face="Times New Roman"
color="#000000"><b>Session 3: Bayesian Clinical Trials: Improving
Cancer Research<br>
</b></font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000"><b>Speaker: Stuart
Bailey</b> (Novartis Pharma) Collaborator: Daniel Lorand
(Novartis)<br>
<b>Title:</b> The Simultaneous Assessment of Safety and Efficacy: An
Application of a Bayesian Model to Determine the Optimal Biological
Dose in Oncology Phase I Dose Escalation<br>
<x-tab> </x-tab><x-tab>
</x-tab><x-tab>
</x-tab><x-tab> </x-tab><br>
<b>Speaker: Brani Vidakovic</b> (Georgia Institute of Technology and
Emory University)<br>
Collaborators: André Rogatko (Samuel Oschin Comprehensive Cancer
Institute), <br>
Mourad Tighiouart (Emory University), and Pulak Ghosh (Novartis
Pharma)</font></div>
<div><font face="Times New Roman" color="#000000"><b>Title:</b>
Individualized Patient Dosing in Cancer Clinical Trials<br>
<br>
<b>Speaker: Andrew Mugglin</b> (University of
Minnesota) <br>
Collaborator: Nathan Enas (Eli Lilly and Company)<br>
<b>Title:</b> An Efficient Randomized Bayesian Phase II Study Design:
A Model and a Case Study<br>
<x-tab>
</x-tab><x-tab>
</x-tab><x-tab>
</x-tab><x-tab> </x-tab><br>
<b>Chair:</b> Sharon-Lise T. Normand (Harvard University)<br>
<br>
1:30 PM - 3:00 PM<x-tab> </x-tab><b>Session 4:
Bayesian Methods Influencing Health Policy<br>
</b></font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000"><b>Speaker: A.
James O'Malley</b> (Harvard University) <br>
Collaborators: Sharon-Lise T. Normand (Harvard University) and Richard
Frank (National Bureau of Economic Research)<br>
<b>Title:</b> Traditional Instrumental Variables Methods Versus
Likelihood and Bayesian Approaches for Comparing Antipsychotic
Medications<br>
</font><font face="Times" color="#000000"><x-tab>
</x-tab><x-tab>
</x-tab><x-tab>
</x-tab><x-tab> </x-tab><br>
</font><font face="Times New Roman" color="#000000"><b>Speaker: Yulei
He</b> (Harvard University) <br>
Collaborators: Bob Wolfe and Sharon-Lise T. Normand (Harvard
University)<br>
<b>Title:</b> The Healthcare World Is Not Flat: Understanding
Geographical Variations in the Quality of Hospital Care<br>
<br>
<b>Speaker: Gillian D. Sanders</b> (Duke University)<br>
Collaborator: Scott Schmidler (Duke University)<br>
<b>Title:</b> Effect of HPV Vaccine Characteristics and Implementation
Strategies on the Incidence of Disease<br>
<br>
<b>Chair:</b> Stacy R. Lindborg (Eli Lilly and Company)<br>
</font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000">3:00 PM - 3:15
PM<b> Break</b></font><font face="Times" color="#000000"><br>
<br>
</font><font face="Times New Roman" color="#000000"><b>Afternoon
Parallel Sessions 5 & 6<br>
</b></font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000">3:15 PM - 4:45
PM<b> Session 5: Bayesian Clinical Trials: Dose Selection
Methods</b></font><font face="Times" color="#000000"><br>
<b><br>
</b></font><font face="Times New Roman" color="#000000"><b>Speaker:
Yu-Hui Chang</b> (University of Iowa) <br>
Collaborators: Kathryn Chaloner and Patricia Winokur (University of
Iowa)<br>
<b>Title:</b> An Adaptive Dose Exploration Design for the Estimation
of Human Colonizing Dose 50 and Human Colonizing Dose 90<br>
<br>
<b>Speaker: François Vandenhende</b> (ClinBAY,
Belgium) <br>
Collaborators: Davorka Tomic, Alexander Coppell, Ping He, Gilmore
O'Neill (Biogen Idec, Inc.), and David J. Brooks (Imperial College,
UK)<br>
<b>Title:</b> Bayesian Dose Selection Strategy in Biomarker Trials: A
Case Study Using Brain Imaging<br>
</font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000"><b>Speaker: Peter
F. Thall</b> (M. D. Anderson)<br>
<b>Title:</b> Utility-based Optimization of Combination Therapy Using
Ordinal Toxicity and Efficacy in Phase I/II Trials<br>
<x-tab>
</x-tab><x-tab>
</x-tab><x-tab> </x-tab><br>
<b>Chair:</b> Andrew Mugglin (University of Minnesota)<br>
</font><font face="Times" color="#000000"><br>
<br>
<br>
</font><font face="Times New Roman" color="#000000">3:15 PM - 4:45
PM <b> Session 6: Bayesian Methods in the Analysis of Clinical
Trial Data</b></font><font face="Times" color="#000000"><br>
<br>
</font><font face="Times New Roman" color="#000000"><b>Speaker: Joseph
W. Hogan</b> (Brown University)<br>
Collaborator: Joo Yeon Lee (FDA)<br>
<b>Title:</b> Construction and Calibration of Priors for Handling
Missing Data in Clinical Trials<br>
<x-tab>
</x-tab><x-tab>
</x-tab><x-tab>
</x-tab><x-tab> </x-tab><br>
<b>Speaker: Zachary Skrivanek</b>, (Eli Lilly and
Company) <br>
Collaborators: Brenda L. Gaydos (Eli Lilly and Company) and Scott M.
Berry (Berry Consultants)<br>
<b>Title:</b> Proof by Simulation: A Case Study<br>
<br>
<b>Speaker: Michael Daniels</b>, (University of Florida,
Gainesville) <br>
Collaborators: C. Wang (University of Florida, Gainesville) and Daniel
O. Scharfstein (Johns Hopkins University)<br>
<b>Title:</b> Bayesian Semiparametric Selection Models with
Application to a Breast Cancer Prevention Trial<br>
</font><font face="Times" color="#000000"><x-tab>
</x-tab><x-tab>
</x-tab><x-tab>
</x-tab><x-tab> </x-tab><br>
</font><font face="Times New Roman" color="#000000"><b>Chair:</b>
Stacy R. Lindborg (Eli Lilly and Company)<br>
<br>
5:30 PM - 8:00 PM<x-tab>
</x-tab><b>Poster Session<br>
</b></font><font face="Times" color="#000000"><b><br>
<br>
</b></font><font face="Times New Roman"
color="#000000"><u><b>Wednesday, January 28, 2009<br>
</b></u></font><font face="Times" color="#000000"><b><br>
</b></font><font face="Times New Roman" color="#000000">8:00 AM - 9:00
AM<x-tab> </x-tab><b>Continental
Breakfast</b> (provided)<br>
</font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000"><b>Morning
Sessions</b></font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000">9:00 AM - 10:30
AM<x-tab> </x-tab><b> Session 7:
Bayesian Decision Theory</b></font><font face="Times"
color="#000000"><br>
<b><br>
</b></font><font face="Times New Roman" color="#000000"><b>Speaker:
David Draper</b> (University of California, Santa Cruz)<br>
<b>Title:</b> Bayesian Decision Theory in Clinical Trial Design and
Analysis: The Utility of Utility<br>
<br>
<b>Speaker: J. Andrés Christen (CIMAT, México)</b> <br>
Collaborators: Peter Müller, J. Kyle Wathen, and Judith Wolf (M. D.
Anderson)<br>
<b>Title:</b> A Bayesian Randomized Clinical Trial: A Decision
Theoretic Sequential Design<br>
<br>
<b>Speaker: Robert Parker</b> (Amgen, Inc.) <br>
Collaborator: Joseph Ibrahim (University of North Carolina)<br>
<b>Title:</b> Assessing Similarity to Existing Drugs to Decide Whether
to Continue Drug Development<br>
<x-tab>
</x-tab><x-tab>
</x-tab><x-tab> </x-tab><br>
<b>Chair:</b> Telba Z. Irony (CDRH, FDA)<br>
<br>
10:30 AM - 10:45 AM <b> Break</b></font><font face="Times"
color="#000000"><br>
<br>
<br>
<br>
<br>
<br>
</font><font face="Times New Roman" color="#000000">10:45 AM - 12:15
PM<x-tab> </x-tab> <b> Session 8: Bayesian Adaptive
Clinical Trials</b></font><font face="Times" color="#000000"><br>
<br>
</font><font face="Times New Roman" color="#000000"><b>Speaker: Jason
T. Connor</b> (Berry Consultants)<br>
Collaborators: Donald A. Berry (M. D. Anderson), Michael Snabes
(BioSante Pharmaceuticals, Inc.), and William White (University of
Connecticut Health Center)<br>
<b>Title:</b> A Phase III Cardiovascular Safety Trial Using A Bayesian
Adaptive Design<br>
</font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000"><b>Speaker: Frank
E. Harrell, Jr.</b> (Vanderbilt University School of Medicine)<br>
<b>Title:</b> Case Study of a Maximally Flexible Bayesian Design in
Biologics Research with a Skeptical Prior and Cox Model-based
Analysis</font></div>
<div><font face="Times New Roman" color="#000000"> <br>
<b>Speaker: Bradley P. Carlin</b>, (University of Minnesota) <br>
Collaborator: Brian Hobbs (University of Minnesota)<br>
<b>Title:</b> Power Priors for Adaptive Incorporation of Historical
Information in Clinical Trials<br>
</font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000"><b>Chair:</b>
Sharon-Lise T. Normand (Harvard University)<br>
</font><font face="Times" color="#000000"><br>
</font><font face="Times New Roman" color="#000000">12:15 PM <b>
Closing Remarks</b> - Program Committee</font><br>
<font face="Times New Roman" color="#000000"></font></div>
<x-sigsep><pre>--
</pre></x-sigsep>
<div><font color="#000000"><br>
<font
size="-1"
>__________________________________________________________________</font
></font></div>
<div><font size="-1" color="#000000"><br></font></div>
<div><font face="Helvetica" size="-1" color="#000000">The Valencia
Mailing List contains about 2,000 entries of people interested in
Bayesian Statistics. It sends information about the Valencia
International Meetings on Bayesian Statistics, and other material of
interest to the Bayesian community.</font></div>
<div><font face="Helvetica" size="-1" color="#000000">If you receive
this message, you are on the Valencia List.<br>
1. If you use an anti-spam programme, please let
<valenciameeting@uv.es> in.<br>
2. If you want to be deleted, please reply
"unsubscribe"</font></div>
<div><font face="Helvetica" size="-1" color="#000000">3. If we are not
using your preferred e-mail address, please reply with the correct
one.</font><br>
<font face="Helvetica" size="-1" color="#000000"></font></div>
<div><font size="-1" color="#000000">Valencia Meetings Mailing List
(c/o Prof. Dr. Jose M. Bernardo)<br>
Dept. Estadistica, Universidad de Valencia</font></div>
<div><font size="-1" color="#000000">Tel +34 96 354 4354 Fax +34 96
364 3560 (direct),</font></div>
<div><font size="-1" color="#000000">Tel +34 96 354 3087, Fax +34 96
354 3238 (office)</font></div>
<div><font size="-1"
color="#000000"><valenciameeting@uv.es> </font></div>
<div><font size="-1" color="#000000"><br></font></div>
<div><font face="Helvetica" color="#000000"><b>Valencia / ISBA Ninth
World Meeting on Bayesian Statistics</b></font></div>
<div><font face="Helvetica" color="#000000"><i>Spain, June
2010</i></font></div>
<div><font color="#000000">www.uv.es/valenciameeting</font></div>
<div><font size="-1"
color="#000000"
>___________________________________________________________________</font
></div>
</body>
</html>